Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Asahi Kasei Pharma Pulls Plug on Liquid Diet Biz
April 21, 2015
- Takeda, Keio, Niigata Univs in Tripartite Research Pact on RNA-Binding Proteins
April 21, 2015
- AbbVie’s Hepatitis C Drug Gets Priority Review in Japan
April 20, 2015
- Nicholas Grund to Come Back as Genzyme Japan President after 8 Months
April 20, 2015
- Takeda’s iPS Cell Deal Potential Game Changer in Drug Research
April 20, 2015
- 60% of 56 Drug Makers Increase Hiring of New Graduates in FY2015; Eisai Resumed Hiring
April 20, 2015
- Ajinomoto to Resume Hiring New Graduates: FY2016 Recruitment Plan
April 20, 2015
- Baxter Files NDA for Advate Successor in Japan
April 17, 2015
- Autologous Cultured Cartilage JACC Becomes Available Across Japan: J-TEC
April 17, 2015
- Takeda Hooks Up with Prof. Yamanaka on iPS Cell Research
April 17, 2015
- Japan’s Generic Market Projected to Top 900 Billion Yen in 2017: Fuji Keizai
April 16, 2015
- JCR Successfully Develops Blood-Brain Barrier-Passing Technology; First Application to Be Drug for Hunter Syndrome
April 16, 2015
- NIID, ID Pharma to Collaborate on Research for Therapeutic Vaccines for AIDS
April 16, 2015
- Nesina’s Cardiovascular Profile Acceptable: FDA Advisory Panel
April 16, 2015
- Lixiana Gains Swiss Nod, First Approval in Europe: Daiichi Sankyo
April 16, 2015
- MSD, Astellas to Develop Januvia-Suglat Combination Drug
April 16, 2015
- Hisamitsu Initiates PIII Study of Transdermal Parkinson’s Disease Treatment Ropinirole in Japan
April 16, 2015
- Eisai to Collaborate with Genomics for Drug Discovery
April 14, 2015
- Japan CSO Association Aims to Double No. of Contract Sales Reps to 8,000 by FY2020
April 14, 2015
- ViiV Healthcare Launches HIV Treatment Triumeq Combination Tablets
April 13, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…